Breaking News

Astex Earns Novartis Milestone

By Kristin Brooks | March 5, 2014

Initiates Phase III trial of LEE011 in advanced breast cancer

Astex Pharmaceuticals has received a milestone payment from Novartis for the commencement, by Novartis, of a Phase III trial of LEE011, a small-molecule inhibitor of cyclin-dependent kinases (CDK) 4 and 6 in postmenopausal woman with advanced breast cancer. LEE011 was discovered under a drug discovery collaboration between Astex and Novartis initiated in December 2005.
LEE011 inhibits CDK4 and CDK6 leading to cell cycle arrest and suppression of DNA synthesis, which may inhibit cancer cell growth. LEE011, in combination with other agents, has shown promising activity in preclinical studies in melanoma and breast cancer.

Related Contract Manufacturing:

blog comments powered by Disqus
  • Solid Dispersions

    Solid Dispersions

    Robert Harris, Juniper Pharma Services||April 5, 2016
    A universal formulation strategy for poorly soluble drugs?

  • Major Regulatory Changes in China to Impact Western Drug Developers

    Major Regulatory Changes in China to Impact Western Drug Developers

    David Deere, PaizaBio||January 28, 2016
    PaizaBio reports on drug development and manufacturing strategies

  • Fit-For-Purpose Assay Development in Bioanalysis

    Fit-For-Purpose Assay Development in Bioanalysis

    Franklin Spriggs, Ligand Binding Assay Group Leader; Ashley Brant, Program Manager, AIT Bioscience||January 28, 2016
    The success of bioanalytical studies relies on the selection of the most suitable analytical method but the timeline of method development and types of analyses involved vary greatly.